Disparity in the era of personalized medicine for epithelial ovarian cancer.

Authors :: Devlin MJ
Miller RE
Source :: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2023 Jan 10; Vol. 15, pp. 17588359221148024. Date of Electronic Publication: 2023 Jan 10 (Print Publication: 2023).
Publication Year :: 2023
Abstract: The treatment of high-grade serous ovarian cancer and high-grade endometrioid ovarian cancer has seen significant improvements in recent years, with BRCA1/2 and homologous recombination status guiding a personalized approach which has resulted in improved patient outcomes. However, for other epithelial ovarian cancer subtypes, first-line treatment remains unchanged from the platinum-paclitaxel trials of the early 2000s. In this review, we explore novel therapeutic approaches being adopted in the treatment of clear cell, mucinous, carcinosarcoma and low-grade serous ovarian cancer and the biological rational behind them. We discuss why such disparities exist, the challenges faced in conducting dedicated trials in these rarer histologies and look towards new approaches being adopted to overcome them.<br />Competing Interests: The authors declare that there is no conflict of interest.<br /> (© The Author(s), 2023.)